부산대학교 도서관

Aim: The aim of this cross‐sectional study is to compare creatinine‐based estimated glomerular filtration rate (eGFRcr) and cystatin C‐based estimated glomerular filtration rate (eGFRcys) between patients with type 2 diabetes receiving and not receiving sodium‐glucose cotransporter 2 (SGLT2) inhibitors. Methods: The plasma specimens from 90 patients with type 2 diabetes who had been receiving SGLT2 inhibitors for at least 24 weeks (SGLT2 inhibitors group) were selected. Meanwhile, the plasma specimens from age‐, sex‐ and BMI‐matched patients with type 2 diabetes not receiving SGLT2 inhibitors (non‐SGLT2 inhibitors group) in 1:1 matching were also selected for comparison. eGFRcr and eGFRcys were calculated using the Chronic Kidney Disease Epidemiology Collaboration equation. Results: When compared with the non‐SGLT2 inhibitors group, eGFRcr was significantly higher in the SGLT2 inhibitors group (70.54 ± 24.87 vs. 79.95 ± 19.57 mL/min/1.73 m2, p = 0.014) while eGFRcys was not different (66.32 ± 24.98 vs 69.17 ± 20.10 ml/min/1.73 m2, p = 0.401). Based on eGFRcr, the chronic kidney disease (CKD) stage in the SGLT2 inhibitors group was lower than that in the non‐SGLT2 inhibitors group, but it was not different when CKD stage was classified by eGFRcys. The difference between eGFRcr and eGFRcys (eGFRcr‐cys) was significantly higher in the SGLT2 inhibitors group (4.22 ± 11.20 vs. 10.78 ± 10.42 ml/min/1.73 m2, p < 0.001). In male patients, there was significant correlation between the eGFRcr‐cys and duration of receiving SGLT‐2 inhibitors (r = 0.398, p = 0.004). This correlation was not found in female patients. Conclusions: There was a discrepancy between eGFRcr and eGFRcys in patients with type 2 diabetes receiving SGLT2 inhibitors when compared with those not receiving SGLT2 inhibitors. [ABSTRACT FROM AUTHOR]